Sunday, April 07, 2019 2:26:22 PM
I just thought I’d share my thought process.
Revenues for 2018 = app 125k
OS = app 1B
To have a pps of $0.01, we are at app. 80x
Now, imagine Q1 revs to be 100k (we know it is going to be more)
Now, assume we don’t add any additional docs and we stabilize at 100k per Q = 400k for 2019. ( we know we’ve adding docs and this number will at least be double = 800k). This also assumes that we make no progress on any other front, including FemCelz, which is already being marketed. Now, all things being equal (no Chang in OS), our pps will be app. $0.04 for 2019.
However, we are adding docs every Q. So, if we add 3 docs per Q - for a full Q, we grow by app. $100k from previous Q - assuming we had Revs of $100k in Q4 with 3 docs fully performing for the entire Q. So, our Revs for 2019, will become, after we increase by $100k per Q by adding 3 docs per Q, app. $1.3M, which at the same 80x, gives us a pps of $0.104. This will be realized after the Q1 2020.
Now, let’s talk about fully diluted pps. If the logic from above holds and we get to 1.3B OS, our pps at the end of this year will be app. $0.08.
As OS increases, 80x will be reduced by app. same %, so worst case, we will see a pps of app. $0.06. This is assuming ‘no changes in every thing else’. This is the ultimate worst case!
Please tell me what u think. If you need details of the math, let me know.
Now, I see that there are many other patents and avenues for generating additional revs. So, reality for me is that the pps will be higher than my estimates. How much higher? Don’t know.
Recent CELZ News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM